Company / Capital Expenditures
ELITE PHARMACEUTICALS INC /NV/ Capital Expenditures History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.6M
FY2024
5-year range
$498.6K / $5.7M
FY2021-FY2024
Trend
+100.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $6M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2024 with a 3-year CAGR of +48.3%.
Declined from $6M to $2M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +48.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +48.3%, indicating consistent growth.
- In FY2024, capital expenditures increased 100.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.6M | +100.7% |
| FY2023 | $809.7K | -85.9% |
| FY2022 | $5.7M | +1050.6% |
| FY2021 | $498.6K | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026